GtoPdb is requesting financial support from commercial users. Please see our sustainability page for more information.

PF-07853578   Click here for help

GtoPdb Ligand ID: 13839

Synonyms: example 11 [O2024084360A1] | PF07853578
Compound class: Synthetic organic
Comment: PF-07853578 is a small molecule inhibitor that is designed to target PNPLA3I148M in fatty liver diseases. It acts as a selective molecular glue type protein degrader. The chemical structure was disclosed during the 'First Time disclosures' session at the ACS Spring 2025 meeting in San Diego and this was matched to example 11 in patent WO2024084360A1 [1].
Click here for help
2D Structure
Click here for help
Click here for structure editor
Physico-chemical Properties
Click here for help
Hydrogen bond acceptors 6
Hydrogen bond donors 0
Rotatable bonds 4
Topological polar surface area 75.3
Molecular weight 408.85
XLogP 2.18
No. Lipinski's rules broken 0

Generated using the Chemistry Development Kit (CDK) (Willighagen EL et al. Journal of Cheminformatics vol. 9:33. 2017, doi:10.1186/s13321-017-0220-4; https://cdk.github.io/)

SMILES / InChI / InChIKey
Click here for help
Canonical SMILES C[C@@H]1CCN([C@@H]2CC(CN(C2)C(=O)OC3=CC=C(C=C3)Cl)(F)F)S1(=O)=O
Isomeric SMILES C[C@@H]1CCN([C@H]2CN(CC(F)(F)C2)C(=O)OC3=CC=C(Cl)C=C3)S1(=O)=O
InChI InChI=1S/C16H19ClF2N2O4S/c1-11-6-7-21(26(11,23)24)13-8-16(18,19)10-20(9-13)15(22)25-14-4-2-12(17)3-5-14/h2-5,11,13H,6-10H2,1H3/t11-,13-/m1/s1
InChI Key LWZQGRRGKYWBQG-DGCLKSJQSA-N

Generated using the Chemistry Development Kit (CDK) (Willighagen EL et al. Journal of Cheminformatics vol. 9:33. 2017, doi:10.1186/s13321-017-0220-4; https://cdk.github.io/)

No information available.
Summary of Clinical Use Click here for help
PF-07853578 is a lead compound that has entered clinical trial.
Clinical Trials
Clinical Trial ID Title Type Source Comment References
NCT05890105 A Study to Learn About the Study Medicine PF-07853578 and How it Acts in the Bodies of Healthy Adults Phase 1 Interventional Pfizer